Fiscal 2026 1st Quarter Financial Results

Supplementary Financial Summary

July 31, 2026

Asahi Kasei Corporation

Detailed supplementary data on business results are now disclosed in the Financial Factbook on our website.
https://www.asahi-kasei.com/ir/library/financial_briefing/

AsahiKASEI
Creating for Tomorrow

Focus of Q1 2026 results and H1 2026 forecast

Asahi KASEI

Q1 2026 results		H1 2026 forecast	
Operating income	**Net income attributable to owners of the parent**	**Operating income**	**Net income attributable to owners of the parent**
¥81.3 billion (YoY +51.5%)	¥53.8 billion (YoY +172.7%)	¥145.0 billion (YoY +34.9%)	¥89.0 billion (YoY +34.3%)
Before goodwill amortization: ¥90.7 billion (+47.0%)		Before goodwill amortization: ¥165.0 billion (+33.3%)	

Q1 2026 results

- **Operating income increased significantly from previous year;** steady income growth in First Priority businesses of Pharmaceuticals, Critical Care, and Electronics; positive effect of inventory valuation in Essential Chemical due to Middle East situation
- **Net income increased significantly from previous year** with nonrecurrence of loss on discontinuation of MMA business etc. in Material, in addition to higher operating income

H1 2026 forecast

- **Both operating income and net income expected to increase from previous year;** firm performance centered on First Priority businesses in Q2, in addition to progress of Q1 results
- Regarding effects of Middle East situation: impact of higher feedstock prices to be largely offset by increasing sales prices; positive effect of inventory valuation remaining but less than in Q1; no current impact on demand, continuing to carefully monitor

Shareholder returns

- FY 2026 interim dividend forecast at ¥22 per share (¥2 per share increase from previous year; unchanged from previous forecast)

Main impacts and risks of Middle East situation (1)

AsahiKASEI

- **Impact of increased feedstock prices due to higher petrochemical market prices to be largely offset by timely and appropriate sales price increases;** positive impact of inventory valuation in Q1, **but the effect is expected to decline in Q2 as market prices subside**
- 3-sector management with Healthcare, Homes, and Material is **highly resilient, and risks of significant impacts on earnings are limited at this time**; supply chain risks and risk of decreased demand mainly in Material to be carefully monitored going forward
- H2 impact to be reviewed as appropriate concurrently with Q2 results

Assumptions regarding impact of Middle East situation on H1 2026 forecast

- **Domestic naphtha price of ¥118,900/kL in Q1, forecasted to be ¥95,000/kL in Q2**
- **Impact of diminished demand due to elevated feedstock prices was immaterial in Q1, expected to be immaterial in Q2**
- **Sales in the Middle East are limited, resulting in immaterial impact**

Segment	Main impacts, risks, and countermeasures related to Middle East situation
Healthcare	• Impact currently immaterial; as supply chain risks may change depending on how the situation develops, carefully monitoring market trends while maintaining appropriate communication with customers and suppliers
Homes	• Supply of necessary materials and components currently obtained; impact of higher procurement costs expected in Q2; as supply chain risks may change depending on how the situation develops, carefully monitoring market trends while maintaining appropriate communication with customers and suppliers
Material	• No significant impact on operation of the ethylene production facility and derivative plants in Mizushima • Effects of elevated feedstock prices due to higher petrochemical market prices are described on the following page • Currently some speculative demand occurring for certain businesses; carefully monitoring market trends while maintaining appropriate communication with customers and suppliers regarding supply chain risks and risk of decreased demand due to higher feedstock costs

Main impacts and risks of Middle East situation (2)

Asahi KASEI

- Impact of increased feedstock prices due to higher petrochemical market prices to be largely offset by timely and appropriate sales price increases
- Significant gain on inventory valuation in Q1 due to increased feedstock prices, but **gain on inventory valuation is expected to diminish due to decreased petrochemical market prices during Q2**

Operating income change factors in Essential Chemical and Performance Chemical



[1] Including inventory variance [2] Excluding effect of foreign exchange

Progress of business portfolio transformation (1)

Asahi KASEI

Business portfolio transformation through proactive growth investments

FY2018[1]



M&A ≈¥1 trillion

Healthcare	Homes	Material
Veloxis, calliditas, itamar medical	Erickson, ODC	SAGE Automotive Interiors

Healthcare

Planova virus removal filters

Material

Pimel photosensitive dielectric

Hipore wet-process LIB separator

Capex (growth-related) ≈¥600 billion

FY2025[1]



Asahi Kasei's ecosystem	Focus on high value-added markets	Strategic capital allocation	Utilizing diverse intangible assets (technology, personnel, management knowledge)

[1] Graph proportions excluding Others category and corporate expenses and eliminations

[2] Total of businesses currently classified as Performance Chemical and Essential Chemical

Progress of business portfolio transformation (2)

AsahiKASEI

- Advancing business portfolio transformation with both growth investments and structural transformation since the previous MTP
- Proactive decisions adopted on growth investments and structural transformation in the first year of the current MTP

Growth investments

FY2022–24 — Previous MTP "Be a Trailblazer"

Life Science
- Acquisition of Bionova Scientific (biologics CDMO)

Pharmaceuticals
- Acquisition of Calliditas Therapeutics

Electronics
- Increased capacity for Pimel semiconductor buffer coat/interlayer dielectric

Overseas Homes
- Acquisition of Focus Companies (Nevada)
- Acquisition of ODC Construction (Florida)

Energy & Infrastructure
- Addition of coating facilities for wet-process LIB separators in U.S. and Japan
- Construction of integrated plant for wet-process LIB separators in North America

FY2025–27 (decisions adopted in FY25, estimated investment amounts shown) — Current MTP "Trailblaze Together"

Electronics
- **Expansion of capacity for Pimel**

  ¥16 billion H1 FY28 commercial start-up

Energy & Infrastructure
- **Expansion of capacity to manufacture system components for clean hydrogen**

  ¥31 billion FY28 commercial start-up

Pharmaceuticals
- **Acquisition of Aicuris**

  ¥144.3 billion Apr. 17, 2026 closing

Life Science
- **Construction of a new spinning plant for Planova (virus removal filter)**

  ¥23.4 billion H2 FY29 commercial start-up

Structural transformation

FY2022–24

Electronics
- Divestiture of pellicles business

Comfort life
- Establishment of joint venture for spunbond nonwovens
- Divestiture of businesses of Asahi Kasei Pax

Essential Chemical
- Discontinuation of acrylonitrile and other operations of PTT Asahi Chemical Co., Ltd.

Construction Materials
- Closure of Iwakuni Plant for AAC

Pharmaceuticals
- Divestiture of diagnostic reagents business

Life Science
- Structural reform of Sepacell business
- Divestiture of blood purification business

FY2025–27

Electronics
- **Discontinuation of UVC LED device production**

Energy & Infrastructure
- **Divestiture of lead battery separator business**

Comfort Life
- **Integration of trading company functions**

Performance Chemical
- **Discontinuation of hexamethylene diamine production**

Essential Chemical
- **Discontinuation of MMA and related businesses**
- **Closure of AMEC[1] naphtha cracker in Mizushima**
- **Reconfiguration of certain derivatives operations at the Mizushima Works**

Critical Care
- **Divestiture of an EMS[2] billing services business**

(shown under fiscal year of decision adoption)

[1] Asahi Kasei Mitsubishi Chemical Ethylene Corp.

[2] Emergency medical services

New business categories and positioning from fiscal 2025

- Reconfiguration of subsegments starting in fiscal 2025 (see Appendix)
- Continuing investments in First Priority and Growth Potential to achieve income growth while advancing reforms for Profitability improvement and business model change

	Healthcare	Homes	Material
First Priority ● Gaining income from past investments ● Continue aggressive investment, including inorganic growth	Pharmaceuticals Critical Care	Overseas Homes	Electronics
Growth Potential ● Growth drivers of future business ● Promote alliance strategies from a competitive perspective	Life Science	Real estate development	Energy & Infrastructure
Earnings Base Expansion ● Generate stable earnings ● Growth investment based on strong awareness of capital efficiency		Order-built, remodeling, Rental/brokerage Construction Materials	Car Interior Comfort Life
Profitability Improvement & Business Model Change ● Restructuring businesses with sluggish earnings/low capital efficiency ● Changing to new business models through utilization of intangible assets			Performance Chemical Essential Chemical

Medium-term changes in composition of operating income (as of May 2026)

AsahiKASEI

Aiming for new record high operating income for 3rd consecutive year in FY 2026 with profit growth in First Priority businesses

Chemical business affected by deteriorating market conditions, but overall operating income generally maintained → **Steady profit growth centered on four First Priority businesses expected**



[1] Sum of operating income of businesses currently included in Pharmaceuticals and Life Science, Critical Care, Overseas Homes, and Electronics

Progress of First Priority businesses (1)

AsahiKASEI

Pharmaceuticals
U.S. sales of Envarsus XR and Tarpeyo



- Sales growth with greater awareness among nephrologists of Tarpeyo as therapy for IgA nephropathy (consolidated in October 2024)
- Nefecon (Tarpeyo) is the only drug recommended for treatment of IgA nephropathy in the 2025 international kidney disease treatment guideline[2]

Critical Care
Sales of ACT and CMS[3]



- ACT performed well with September 2025 launch of new defibrillator product, etc.
- CMS performed well with firm shipments of LifeVest; increased demand with effectiveness newly confirmed by clinical study in Germany[4]

[1] Sales recorded from October 2024 with consolidation [2] KDIGO 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)
[3] Results from Q1 2022 to Q1 2023 aligned to the current categories by simplified calculation for reference
[4] Large-scale clinical study performed mainly at academic institutions from December 2021 to May 2023 in Germany to evaluate cardiac arrest risk during early treatment period, with ZOLL LifeVest used.

Progress of First Priority businesses (2)

AsahiKASEI

Overseas Homes
Sales in North America and Australia



- Weak demand persisting in North America, but increased sales with gradual recovery of demand in Australia from FY 2025
- Solid market growth anticipated in both North America and Australia with firm demand over the medium-to-long term

Electronics
Sales of main products

(FY 2022 sales indexed to 100)



- Firm sales of Pimel centered on AI applications; advancing investment to meet growing demand, further growth forecasted
- Firm sales of glass fabric centered on AI applications; improved product mix with advance of transition to high value-added low-dielectric products

Efforts to raise corporate value

- Measures for sustainable increase in corporate value centered on accelerating business portfolio transformation and improving profitability
- Introducing special incentive program for employee stockholding association beginning in fiscal 2026 to heighten awareness for raising corporate value among management and employees

Measures to raise corporate value

Accelerating business portfolio transformation

- **Steadily reaping fruits of investments in First Priority businesses while accelerating structural transformation of low capital efficiency businesses in Material with ROIC persistently below WACC**

Improving profitability

- **In addition appropriate price increases, decreased sales of general-purpose products, and cost reductions through procurement process reform, advancing measures to optimize organizational functions**

Enhancing investment management

- **Strengthening the management of hurdle rates and other factors to enhance investment decisions on growth investments; thoroughly monitoring and following up on investments**

Optimizing capital policy

- **Strengthening shareholder returns from the perspective of appropriate capital levels, and continuous reduction of strategic shareholdings** (≈70% reduction of stocks, >¥180 billion reduction of holdings over the past 5 years)

Reducing the cost of capital

- **Disclosure of strategies for acquisitions, large-scale investments, etc., and initiatives to strengthen management foundations, as well as ongoing enrichment of dialogue with investors**

PBR (price to book value ratio)[1]



ROE and PER (price to earnings ratio)[1]



[1] PBR and PER based on closing price at fiscal year end

1. Consolidated results for Q1 2026

Q1 2026 consolidated financial results

AsahiKASEI

- Net sales increased by ¥87.8 billion (+11.9%) to ¥826.2 billion
- Operating income increased by ¥27.7 billion (+51.5%) to ¥81.3 billion
- Net income attributable to owners of the parent increased by ¥34.1 billion (+172.7%) to ¥53.8 billion

		Q1 2025	Q1 2026	Increase (decrease)	% change
Net sales	(¥ billion)	738.3	826.2	87.8	+11.9%
Operating income	(¥ billion)	53.7	81.3	27.7	+51.5%
Operating margin		7.3%	9.8%	+2.6%	
Operating income before goodwill amortization	(¥ billion)	61.7	90.7	29.0	+47.0%
EBITDA[1]	(¥ billion)	100.9	133.9	32.9	+32.6%
EBITDA margin		13.7%	16.2%	+2.5%	
Net income attributable to owners of the parent	(¥ billion)	19.7	53.8	34.1	+172.7%

Exchange rate, naphtha price		
¥/US$ exchange rate (market average)	145	160
¥/€ exchange rate (market average)	164	185
Naphtha price (¥/kL, domestic)	66,300	118,900

[1] EBITDA = operating income, depreciation, and amortization (tangible, intangible, and goodwill)

Operating income change factors

AsahiKASEI

- Substantive increase of ¥8.1 billion excluding impact of foreign exchange, market prices, and one-time factors
- Increased sales of mainstay products particularly in First Priority businesses of Pharmaceuticals, Critical Care, and Electronics



[1] Inventory valuation and terms of trade in Essential Chemical and Performance Chemical, and change in unrealized gain on inventory in Material

Q1 2026 results by segment

AsahiKASEI

Sales (YoY)	Operating income (YoY)
+¥87.8 billion (+11.9%)	+¥27.7 billion (+51.5%)



Operating income change factors

Healthcare	+¥7.1 billion
Increased SG&A expenses and impact of consolidation of Aicuris, but increased income with sales growth of mainstay products in each business and positive effect of weaker yen, etc.	
Pharmaceuticals & Life Science	+¥**3.6** billion
Critical Care	+¥**3.6** billion

Homes	-¥2.2 billion
Higher average unit prices in domestic order-built homes, but decreased income in Housing with lower demand and lower pricing in North American business	
Housing	-¥**1.9** billion
Construction Materials	-¥**0.3** billion

Material	+¥23.9 billion
Increased income with greater shipments of mainstay products in Electronics, positive impact of inventory valuation in Essential Chemical and Performance Chemical due to Middle East situation, and positive effect of weaker yen, etc.	
Electronics[1]	+¥**4.5** billion
Car Interior	+¥**1.2** billion
Energy & Infrastructure[1]	-¥**2.5** billion
Comfort Life	+¥**1.5** billion
Performance Chemical	+¥**9.2** billion
Essential Chemical	+¥**17.2** billion
Others in Material[1]	-¥**7.1** billion

[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

Non-operating income/expenses, extraordinary income/loss and income taxes

- Non-operating income/expenses improved with improved foreign exchange gains/losses and equity in earnings/losses of affiliates
- Extraordinary income/loss improved significantly with nonrecurrence of previous year's loss on discontinuation of MMA business etc. in Material
- Income taxes increased with nonrecurrence of previous year's tax effect of structural transformation in Healthcare, in addition to higher income before income taxes

(¥ billion)

	Q1 2025	Q1 2026	Increase (decrease)
Net non-operating income (expenses)	(3.7)	4.0	7.7
Gain on sales of investment securities	0.4	2.3	2.0
Gain on sales of noncurrent assets	0.1	0.4	0.3
Settlement income	4.3	–	(4.3)
Gain on sale of shares of subsidiaries and affiliates	7.5	–	(7.5)
Total extraordinary income	12.2	2.7	(9.6)
Loss on disposal of noncurrent assets	1.6	1.1	(0.5)
Impairment loss	0.8	0.1	(0.7)
Loss on cancellation of electricity contract	4.2	–	(4.2)
Business structure improvement expenses	29.9	0.3	(29.5)
Total extraordinary loss	36.4	1.5	(34.9)
Net extraordinary income (loss)	(24.2)	1.1	25.3
Income taxes	4.7	30.3	25.6

Balance sheets

- Total assets increased by ¥318.8 billion with increased goodwill and other intangible assets due to consolidation of Aicuris in Healthcare, increased inventories in Homes and Material, and increased yen value of assets due to weaker yen, etc.
- Net worth increased with higher accumulated other comprehensive income due to weaker yen, but D/E ratio rose from the previous fiscal year-end as with increased interest-bearing debt to fund the acquisition of Aicuris

(¥ billion)

	At end of Jun. 2026	Vs end of Mar. 2026		At end of Jun. 2026	Vs end of Mar. 2026
Current assets	1,974.8	109.4	Liabilities	2,260.1	287.8
Cash and deposits	387.4	10.3	Accounts payable	218.2	23.2
Accounts receivable	525.7	11.9	Interest-bearing debt[1]	1,205.3	237.7
Inventories	869.9	76.2	Other liabilities	836.6	26.8
Other current assets	191.8	11.0	Net assets	2,196.7	31.1
Noncurrent assets	2,482.0	209.4	Net worth	2,116.9	28.4
Property, plant and equipment	994.5	33.4	Shareholders' equity	1,474.3	6.0
Goodwill	424.4	40.6	Accumulated other comprehensive income	642.6	22.4
Other intangible assets	672.7	138.6	Non-controlling interests	79.8	2.6
Investment securities	138.1	(2.1)			
Other noncurrent assets	252.3	(1.1)			
Total assets	**4,456.8**	**318.8**	**Total liabilities and net assets**	**4,456.8**	**318.8**

Interest-bearing debt and D/E ratio



[1] Excluding lease obligations

Notes: ¥160/US$ and ¥183/€ as of March 31, 2026
¥162/US$ and ¥185/€ as of June 30, 2026

Cash flows

AsahiKASEI

Operating CF	Higher income before income taxes due to income growth centered on First Priority businesses, but cash inflow even with previous year with greater working capital associated with increased inventories due to higher feedstock costs in Material, etc.
Investing CF	Cash outflow increased significantly with higher disbursement related to M&A due to Aicuris acquisition, and lower proceeds from sale of shares in subsidiaries compared to previous year with business divestiture in Healthcare

(¥ billion)

Operating CF (inflow)



Investing CF (outflow)

Outlays for M&A
Outlays for capital expenditure, and other investing CF



Free cash flow (inflow)



2. Forecast for H1 2026

H1 2026 forecast (consolidated)

AsahiKASEI

- Net sales expected to increase by ¥199.6 billion (+13.4%) to ¥1,686.0 billion
- Operating income expected to increase by ¥37.5 billion (+34.9%) to ¥145.0 billion
- Net income attributable to owners of the parent expected to increase by ¥22.7 billion (+34.3%) to ¥89.0 billion

		Q1	Q2	H1 2025	Q1	Q2 forecast	H1 2026 forecast	Increase (decrease)	% change
Net sales	(¥ billion)	738.3	748.0	1,486.4	826.2	859.8	1,686.0	199.6	+13.4%
Operating income	(¥ billion)	53.7	53.8	107.5	81.3	63.7	145.0	37.5	+34.9%
Operating margin		7.3%	7.2%	7.2%	9.8%	7.3%	8.5%	+1.3%	
Operating income before goodwill amortization	(¥ billion)	61.7	62.1	123.8	90.7	74.3	165.0	41.2	+33.3%
EBITDA [1]	(¥ billion)	100.9	102.0	202.9	133.9	124.1	258.0	55.1	+27.1%
EBITDA margin		13.7%	13.6%	13.7%	16.2%	14.3%	15.2%	+1.6%	
Net income attributable to owners of the parent	(¥ billion)	19.7	46.5	66.3	53.8	35.2	89.0	22.7	+34.3%
EPS	(¥)			48.79			66.13	17.34	+35.5%
EPS before goodwill amortization	(¥)			60.81			80.99	20.18	+33.2%

Exchange rate/naphtha price	Q1	Q2	H1 2025	Q1	Q2 forecast	H1 2026 forecast
¥/US$ exchange rate (market average)	145	147	146	160	155	157
¥/€ exchange rate (market average)	164	172	168	185	180	183
Naphtha price (¥/kL, domestic)	66,300	63,200	64,800	118,900	95,000	107,000
Dividends per share (¥)			20			22

[1] EBITDA = operating income, depreciation, and amortization (tangible, intangible, and goodwill)

H1 2026 forecast by segment (year-on-year)

AsahiKASEI

Sales (YoY)	Operating income (YoY)
+¥**199.6** billion (+13.4%)	+¥**37.5** billion (+34.9%)



Operating income change factors

Healthcare	**+¥12.9 billion**
Increased SG&A expenses and impact of consolidation of Aicuris, but increased income with sales growth of mainstay products in each businesses and positive effect of weaker yen	
Pharmaceuticals & Life Science	+¥**4.8** billion
Critical Care	+¥**8.3** billion

Homes	**-¥2.1 billion**
Decreased income in Housing with higher material costs and higher fixed costs in domestic order-built homes, and lower housing demand and lower pricing in North American business	
Housing	-¥**1.5** billion
Construction Materials	-¥**0.5** billion

Material	**+¥28.0 billion**
Increased income with grater shipments of mainstay products in Electronics, positive impact of inventory valuation due to Middle East situation in Essential Chemical and Performance Chemical, and positive effect of weaker yen	
Electronics[1]	+¥**6.4** billion
Car Interior	+¥**1.1** billion
Energy & Infrastructure	-¥**3.0** billion
Comfort Life	+¥**2.6** billion
Performance Chemical[1]	+¥**9.0** billion
Essential Chemical	+¥**17.1** billion
Others in Material[1]	-¥**5.2** billion

[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

Shareholder returns

- Fiscal 2026 dividends **forecasted to increase by ¥2 to ¥44 per share** in line with shareholder returns policy; **interim dividend forecast of ¥22 per share**
- Share repurchase of up to ¥40 billion decided in November 2025 currently in progress (repurchase period from November 6, 2025, to October 31, 2026)



	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025 [3]	FY 2026 forecast in May
Dividends per share (¥)	34	34	36	36	38	42	44
Dividend payout ratio	59.1%	29.1%	-	113.9%	38.8%	35.9%	36.8%
Net worth (¥ billion)	1,467.5	1,687.4	1,660.3	1,813.4	1,859.4	2,088.5	2,065.3
Shareholders' equity[2] (¥ billion)	1,335.9	1,459.4	1,317.5	1,311.9	1,366.8	1,468.3	1,529.0

Shareholder returns policy

1. Determining level of shareholder returns based on medium-term FCF outlook
2. Aiming for medium- to long-term progressive dividends with **DOE of 3% as a benchmark**
3. Share repurchase is decided by comprehensively considering optimal capital structure, investment projects, cash flow, and share price conditions

[1] Adjusted DOE (dividends on equity) = total dividends ÷ shareholders' equity [2] Shareholders' equity = Net worth - accumulated other comprehensive income
[3] Share repurchase of ¥40.0 billion is the maximum amount decided on November 5, 2025, not the actual amount repurchased

3. Results by segment

Healthcare Sales and operating income increase/decrease

AsahiKASEI

Operating income increased with negative impact of others such as increased SG&A expenses and new consolidation of Aicuris outweighed by positive sales volume factor due to greater shipments of mainstay products

Operating income increase/decrease



	Sales				Operating income							
									Increase (decrease) due to:			
	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Sales volume	Sales prices[1]	Foreign exchange[2]	Others[3]
Healthcare Segment	155.1	**190.8**	35.7	+23.0%	22.7	**29.8**	7.1	+31.4%	8.6	1.5	0.3	(3.3)
Pharmaceuticals & Life Science	65.6	**80.0**	14.4	+22.0%	16.2	**19.8**	3.6	+22.3%	4.2	0.3	0.1	(1.0)
Critical Care	89.6	**110.8**	21.2	+23.7%	6.4	**10.0**	3.6	+55.5%	4.4	1.3	0.2	(2.2)

[1] Excluding effect of foreign exchange. [2] Effect of foreign exchange associated with sales prices.
[3] Including foreign currency translation adjustment, fixed cost variance, and nonrecurring income/expense related to licensing, new consolidations, etc.

Pharmaceuticals & Life Science

AsahiKASEI

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025

- **Pharmaceuticals:** Impact of consolidation of Aicuris, but operating income increased with greater shipments of mainstay products
- **Life Science:** Operating income increased with greater shipments of Planova and positive effect of weaker yen

Business strategy in the current MTP

Pharmaceuticals — First Priority

- Income growth of Envarsus XR (Veloxis), Tarpeyo (Calliditas), and mainstay domestic products
- Continuing growth investment focused on therapeutic areas of autoimmune disease, kidney disease, transplantation, and severe infectious disease, etc. (Aicuris acquisition in April 2026, planning total in-licensing of ≈¥40 billion during 3-year period of MTP)

Life Science — Growth Potential

- Firm growth of Planova (virus removal filters)
- Strengthening the fundamentals and reconfiguring the strategy of Bionova (CDMO)

U.S. sales of Envarsus XR and Tarpeyo



[1] Sales recorded from October 2024 with consolidation

Healthcare

Main pharmaceuticals

		(Sales region, monetary unit)	FY 2025		FY 2026	Q1 2026 vs Q1 2025	
			Q1	H1	Q1	Increase (decrease)	% change
U.S. Business	Envarsus XR	(US, $ million)	85	167	99	14	+16.5%
	Tarpeyo	(US, $ million)	84	164	95	10	+12.4%
Japan Business	Teribone	(Japan, ¥ billion)	10.9	21.8	10.4	(0.5)	-4.2%
	Reclast	(Japan, ¥ billion)	0.3	0.6	0.3	(0.0)	-8.6%
	Kevzara	(Japan, ¥ billion)	3.0	6.1	3.6	0.6	+20.3%
	Plaquenil	(Japan, ¥ billion)	0.6	1.1	0.4	(0.2)	-36.0%
	Recomodulin	(Japan, ¥ billion)	1.5	3.2	1.5	(0.1)	-5.2%
	Cresemba	(Japan, ¥ billion)	1.5	3.1	2.1	0.6	+43.3%
	Empaveli	(Japan, ¥ billion)	0.5	1.0	0.3	(0.2)	-47.7%
	Doptelet	(Japan, ¥ billion)	0.0	0.1	0.8	0.8	+4,906.6%

Product name	Generic name	Classification	Indication	Formulation
Envarsus XR	Tacrolimus extended-release tablets	Immunosuppressant drug	Suppression of kidney transplant rejection	Tablet
Tarpeyo	Budesonide delayed release capsules	Kidney disease therapeutic agent	Primary IgA nephropathy with risk of disease progression	Capsule
Teribone	Teriparatide acetate	Synthetic human parathyroid hormone (PTH)	Osteoporosis with high risk of fracture	Injection
Reclast	Zoledronic acid	Osteoporosis drug	Osteoporosis	Injection
Kevzara	Sarilumab (rDNA origin)	Interleukin-6 inhibitor	Rheumatoid arthritis not responding well to conventional treatments	Injection
Plaquenil	Hydroxychloroquine sulfate	Immunomodulator	Cutaneous lupus erythematosus, systemic lupus erythematosus	Tablet
Recomodulin	Recombinant thrombomodulin alfa	Anticoagulant	Disseminated intravascular coagulation	Injection
Cresemba	Isavuconazonium sulfate	Antifungal agent	Aspergillosis, mucormycosis, cryptococcosis	Capsule, Injection
Empaveli	Pegcetacoplan	Complement protein C3 inhibitor	Paroxysmal nocturnal hemoglobinuria	Injection
Doptelet	Avatrombopag maleate	Thrombopoietin receptor agonist	Persistent and chronic immune thrombocytopenia (ITP), etc.	Tablet

Healthcare

Pharmaceuticals pipeline

AsahiKASEI

Development stage	Code name, generic name	Indication	Origin	Development	Region/remarks
Phase III	TA799, apraglutide	Short bowel syndrome	Licensed	Licensor	Phase I in Japan was conducted by Asahi Kasei Pharma
Phase III	ART-123, recombinant thrombomodulin alfa	Chemotherapy-induced peripheral neuropathy (CIPN)	In-house	In-house	Additional indication Joint U.S.-Japan Phase I study complete
Phase III	MN-10-T, teriparatide acetate **New**	Osteoporosis with high risk of fracture	In-house	In-house	Evaluating safety and efficacy for patients who have completed 24 months of treatment
Phase II	AK1830	Pain associated with osteoarthritis	Licensed	In-house	
Phase II	AK1830	Chronic low back pain	Licensed	In-house	
Phase I	AK1910	Autoimmune diseases	Licensed	In-house	
Phase I	AK1960	Various diseases which are difficult to control, such as refractory chronic kidney disease	Licensed	In-house	
Phase I	AK1940	Autoimmune diseases	In-house (joint research)	In-house	
Filed (overseas)	Pritelivir	Acyclovir-resistant HSV infection in immunocompromised patients	In-house (Aicuris)	In-house	United States, etc.
Phase III (overseas)	ART-123, recombinant thrombomodulin alfa	Severe sepsis with coagulopathy	In-house	In-house	United States, Europe, etc.
Phase I (overseas)	VEL-101	SOT (solid organ transplant)	Licensed	In-house	United States, etc.
Phase I (overseas)	AIC468	BK virus infection in kidney transplant patients	Licensed	In-house	United States, etc.

Healthcare

Critical Care

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025

- **ACT:** Higher SG&A expenses and production costs, but operating income increased with greater shipments of new defibrillator product launched in September 2025 and higher selling prices
- **CMS:** Operating income increased with greater number of new patients for LifeVest and higher revenue per patient
- **Sleep apnea diagnosis device:** Operating income increased with greater shipments

Business strategy in the current MTP

Critical Care

First Priority

- Steady growth with rising market share for professional defibrillators, AEDs, etc. in ACT[1]
- Greater penetration of potential market for LifeVest in CMS[2]
- Create demand and expand earnings for new devices such as sleep apnea diagnosis and treatment devices (Itamar, Respicardia), etc.

Sales of ACT and CMS[3]



[1] Acute Care Technology: Professional defibrillators, AEDs, CPR-related, temperature management, software solutions, etc.
[2] Cardiac Management Solutions: LifeVest wearable defibrillators, cardiac disease diagnosis and management, etc. [3] Results from Q1 2022 to Q1 2023 aligned to the current categories by simplified calculation for reference purposes

Sales and operating income increase/decrease

Positive effect of sales factor and decreased fixed costs in domestic order-built homes, but operating income decreased with negative impact in overseas business due to diminished housing demand in North America, etc.

■ Operating income increase/decrease

(¥ billion)



	Sales				Operating income				Increase (decrease) due to:				
									Order-built homes				
	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Sales	Marginal Profit	Fixed cost	Overseas	Others
Homes segment	258.9	**267.6**	8.7	+3.3%	22.4	**20.2**	(2.2)	-9.7%	0.4	(0.0)	0.3	(2.8)	(0.0)
Housing	248.0	**257.9**	9.8	+4.0%	21.0	**19.1**	(1.9)	-8.9%	0.4	(0.0)	0.3	(2.8)	0.3 [1]
Construction Materials	10.9	**9.7**	(1.2)	-10.9%	1.4	**1.1**	(0.3)	-22.2%	-	-	-	-	(0.3)

[1] Development, Rental/brokerage, Remodeling, etc.

Homes

Housing (Order-built, Development, Rental/brokerage, Remodeling, Construction Materials)

AsahiKASEI

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025

- **Order-built homes:** Impact of higher material costs, but operating income increased with effect of higher average unit prices resulting from larger and higher value-added units and lower fixed costs
- **Development:** Operating income decreased with lower number of condominium units sold and weaker mix of units
- **Rental/brokerage:** Operating income increased with firm growth in number of units under management

Business strategy in the current MTP

Real estate development — Growth Potential

- Reinforcing land purchasing and expanding business utilizing the land

Order-built homes, Rental/brokerage, Remodeling, Construction Materials — Earnings Base Expansion

- Strengthen profitability of the order-built homes business with larger and higher added value units and expanded apartment buildings business

Trends in orders received for order-built homes

(percentage change from previous year)

(¥ billion)



[1] Allocation of shared costs has been changed from fiscal 2025. See p. 40.

Housing (Overseas Homes)

AsahiKASEI

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025

- **North American:** Operating income decreased with lower volume of work and lower pricing due to diminished housing demand
- **Australian:** Operating income increased with greater volume of work due to gradual recovery of housing demand

Business strategy in the current MTP

Overseas Homes

Growth Potential

- Reinforcing the Synergos model[1] and sustainable growth by expanding regional coverage in North American business
- Expand market share in Australia and improve profitability and capital efficiency by reforming operational processes in Australian business

Sales in North America and Australia



[1] A business model that integrates core steps of the construction process for shortening the construction period and providing high quality homes

Material

Sales and operating income increase/decrease

Operating income increased with positive effect of sales volume due to firm sales in Electronics, impact of feedstock costs due to Middle East situation outweighed by sales prices due to price increases and foreign exchange due to weaker yen, and positive impact of others due to impact of inventory valuation in Essential Chemical, etc.

Operating income increase/decrease

(¥ billion)



	Sales				Operating income								
									Increase (decrease) due to:				
	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Q1 2025	**Q1 2026**	Increase (decrease)	% change	Sales Volume	Sales prices[1]	Feedstock cost[1]	Foreign exchange[2]	Others[3]
Material Segment	316.6	**360.2**	43.6	+13.8%	14.9	**38.8**	23.9	+160.4%	4.6	27.2	(30.4)	8.1	14.4
Electronics[5]	37.6	**44.1**	6.5	+17.3%	5.4	**9.9**	4.5	+84.2%	2.2	0.7	-	2.0	(0.4)
Car Interior	39.0	**43.5**	4.5	+11.5%	2.1	**3.3**	1.2	+55.9%	(0.5)	1.1	0.4	0.5	(0.4)
Energy & Infrastructure[5]	30.0	**23.9**	(6.1)	-20.3%	1.2	**(1.3)**	(2.5)	–	0.8	(0.5)	(0.3)	0.9	(3.5)
Comfort Life	60.8	**71.0**	10.1	+16.6%	4.1	**5.5**	1.5	+35.7%	2.0	(0.4)	(0.1)	0.7	(0.7)
Performance Chemical	55.7	**61.0**	5.3	+9.5%	(0.7)	**8.4**	9.2	–	0.6	3.2	(2.5)	2.0	5.9
Essential Chemical	91.5	**114.9**	23.4	+25.5%	1.5	**18.6**	17.2	+1182.3%	(0.5)	23.0	(29.7)	2.0	22.4[4]
Others in Material[5]	1.8	**1.7**	(0.1)	-4.9%	1.4	**(5.7)**	(7.1)	–	-	-	1.8[4]	-	(8.9)[4]

[1] Excluding effect of foreign exchange. [2] Effect of foreign exchange associated with sales prices and feedstock costs. [3] Foreign currency translation adjustment, fixed costs, inventory valuation, etc. [4] "Others" in operating income of Essential Chemical includes increase/decrease related to internal sales price which correlates with "Feedstock cost" for the segment; to compensate, corresponding positive and negative figures are shown as "Feedstock cost" and "Others" of Others in Material. [5] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

Electronics

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025

- **Electronic materials:** Operating income increased with firm performance of mainstay products centered on AI applications and positive effect of weaker yen
- **Electronic devices:** Operating income increased with greater shipments of current sensors for EVs etc. and positive effect of weaker yen (lower shipments of products for camera modules due to impact of memory shortage on smartphone demand)

Business strategy in the current MTP

Electronics

First Priority

- Propose optimal materials for the advanced semiconductor package market based on experience in semiconductor chips and materials for substrates and packaging processes in electronic materials
- Especially, expand production capacity for Pimel as semiconductor buffer coat/interlayer dielectric with strong demand in the growing field of cutting-edge semiconductor for AI servers
- Development and commercialization of new electronic materials

Sales of main products[3]



[3] FY 2022 sales indexed to 100

[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

Car Interior

AsahiKASEI

Operating income (¥ billion)



Operating income change factors

Q1 2026 vs Q1 2025	Operating income increased with firm sales in Europe and positive effect of weaker yen, etc.

Business strategy in the current MTP

Car Interior

Earnings Base Expansion

- Firm income growth as a solution-providing business with adaptability leveraging a product lineup matching customer needs, innovative design, and advanced processing and finishing
- Expanding business platform with regionally optimized manufacturing in the U.S., Europe, Japan, and China

Sales of Sage Automotive Interiors



Material

Energy & Infrastructure

AsahiKASEI

■ Operating income (¥ billion)



■ Operating income change factors

Q1 2026 vs Q1 2025	
	● **Separators:** Greater shipments of LIB separators, but operating income decreased with Hipore impacted by application mix and higher fixed costs due to operation of facilities as sales expanded, in addition to impact of divestiture of lead battery separator business ● **Ion-exchange membrane:** Operating income even with previous year with firm performance

Business strategy in the current MTP

Energy & Infrastructure

Growth Potential

- Establishing sales portfolio for stable future earnings in the separator business by expanding sales in ESS applications, etc.; start-up of Canadian plant to be appropriately controlled to maximize earnings (assuming a delay of 1.5–2 years from initial plan)
- Enhance capacity for expansion and steady income growth based on long-standing business foundations as a solution provider in the ion-exchange membrane process chlor-alkali business; applying accumulated business foundations to alkaline water electrolysis for hydrogen production

■ Sales volume and EBITDA trends for Hipore



[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

[2] Energy storage systems, including data center-related

Comfort Life, Performance Chemical, Essential Chemical

AsahiKASEI

Operating income (¥ billion)

Operating income
Operating margin

Earnings Base Expansion

Comfort Life



Profitability improvement & business model change

Performance Chemical



Profitability improvement & business model change

Essential Chemical



Operating income change factors

Q1 2026 vs Q1 2025	Operating income increased with speculative demand on Consumables related to Middle East situation, firm shipments of various products, and positive effect of weaker yen
Q1 2026 vs Q1 2025	Operating income increased with positive effect of inventory valuation due to higher petrochemical market prices, improved performance due to structural transformation (discontinuation of HMD production in Apr. 2027), and positive effect of weaker yen
Q1 2026 vs Q1 2025	Operating income increased with positive effect of inventory valuation due to higher petrochemical market prices and nonrecurrence of previous year's maintenance turnaround

Net sales breakdown by segment

AsahiKASEI

(¥ billion)

	Q1 2025	Q2 2025	H1 2025	Q1 2026	Q2 2026 forecast	H1 2026 forecast	%change Q1 2026 vs Q1 2025	%change H1 2026 vs H1 2025
Healthcare segment	**155.1**	**151.7**	**306.8**	**190.8**	**190.2**	**381.0**	**+23.0%**	**+24.2%**
Pharmaceuticals & Life Science	65.6	62.1	127.6	80.0	79.0	159.0	+22.0%	+24.6%
Pharmaceuticals	50.2	49.4	99.6	61.7	62.3	124.0	+23.0%	+24.5%
Life Science	15.4	12.7	28.1	18.3	16.7	35.0	+18.9%	+24.7%
Critical Care	89.6	89.6	179.2	110.8	111.2	222.0	+23.7%	+23.9%
Homes segment	**258.9**	**267.6**	**526.5**	**267.6**	**304.4**	**572.0**	**+3.3%**	**+8.6%**
Housing	248.0	257.1	505.1	257.9	292.1	550.0	+4.0%	+8.9%
Order-built	102.5	108.7	211.2	103.0	111.5	214.5	+0.5%	+1.5%
Development	14.0	11.2	25.1	13.8	21.2	35.0	-1.2%	+39.3%
Rental/brokerage	43.9	46.6	90.5	47.8	50.7	98.5	+8.8%	+8.9%
Remodeling	13.3	16.7	30.0	14.8	20.2	35.0	+11.6%	+16.7%
Overseas Homes	73.6	73.0	146.6	78.2	87.3	165.5	+6.2%	+12.9%
Others	0.8	0.9	1.7	0.4	1.1	1.5	-54.4%	-12.7%
Construction Materials	10.9	10.5	21.3	9.7	12.3	22.0	-10.9%	+3.2%
Material segment	**316.6**	**321.3**	**637.8**	**360.2**	**359.8**	**720.0**	**+13.8%**	**+12.9%**
Electronics[1]	37.6	41.1	78.8	44.1	44.9	89.0	+17.3%	+13.0%
Car Interior	39.0	40.2	79.2	43.5	41.5	85.0	+11.5%	+7.3%
Energy & Infrastructure	30.0	33.0	63.1	23.9	24.1	48.0	-20.3%	-23.9%
Comfort Life	60.8	63.9	124.8	71.0	69.0	140.0	+16.6%	+12.2%
Performance Chemical	55.7	56.6	112.4	61.0	61.0	122.0	+9.5%	+8.6%
Essential Chemical	91.5	84.5	176.0	114.9	117.1	232.0	+25.5%	+31.8%
Others in Material[1]	1.8	1.9	3.7	1.7	2.3	4.0	-4.9%	+8.7%
Others	7.7	7.5	15.2	7.7	5.3	13.0	-0.8%	-14.7%
Consolidated	**738.3**	**748.0**	**1,486.4**	**826.2**	**859.8**	**1,686.0**	**+11.9%**	**+13.4%**

[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

Operating income breakdown by segment

AsahiKASEI

(¥ billion)

	Q1	Q2	H1 2025	Q1	Q2 forecast	H1 2026 forecast	% change Q1 2026 vs Q1 2025	% change H1 2026 vs H1 2025
Healthcare segment	**22.7**	**17.4**	**40.1**	**29.8**	**23.2**	**53.0**	**+31.4%**	**+32.2%**
Pharmaceuticals & Life Science	16.2	12.4	28.6	19.8	13.6	33.4	+22.3%	+16.9%
Critical Care	6.4	5.1	11.5	10.0	9.8	19.8	+55.5%	+71.9%
Homes segment	**22.4**	**24.2**	**46.6**	**20.2**	**24.3**	**44.5**	**-9.7%**	**-4.4%**
Housing	21.0	22.8	43.8	19.1	23.2	42.3	-8.9%	-3.5%
Order-built	8.2	11.7	19.9	8.8	10.1	18.9	+7.7%	-5.0%
Development	4.5	2.5	7.0	4.0	3.2	7.2	-11.2%	+3.1%
Rental/brokerage	4.5	4.2	8.8	5.2	4.8	10.0	+14.5%	+14.7%
Remodeling	1.0	2.2	3.1	1.0	3.1	4.0	+1.1%	+28.6%
Overseas Homes	2.3	1.6	3.9	(0.5)	1.7	1.2	-	-69.3%
Others	0.5	0.7	1.2	0.6	0.3	0.9	+23.8%	-20.2%
Construction Materials	1.4	1.4	2.7	1.1	1.1	2.2	-22.2%	-19.6%
Material segment	**14.9**	**16.0**	**31.0**	**38.8**	**20.2**	**59.0**	**+160.4%**	**+90.6%**
Electronics[1]	5.4	7.3	12.6	9.9	9.1	19.0	+84.3%	+50.5%
Car Interior	2.1	2.0	4.2	3.3	2.0	5.3	+55.9%	+27.2%
Energy & Infrastructure[1]	1.2	(1.1)	0.2	(1.3)	(1.5)	(2.8)	-	-
Comfort Life	4.1	4.2	8.2	5.5	5.3	10.8	+35.7%	+31.6%
Performance Chemical[1]	(0.7)	3.5	2.7	8.4	3.4	11.8	-	+329.9%
Essential Chemical	1.5	1.2	2.6	18.6	1.1	19.7	+1182.3%	+647.5%
Others in Material[1]	1.4	(0.9)	0.4	(5.7)	0.9	(4.8)	-	-
Others	0.4	1.7	2.1	0.3	1.0	1.3	-18.4%	-37.6%
Corporate expenses and eliminations	(6.6)	(5.6)	(12.2)	(7.7)	(5.1)	(12.8)	-	-
Consolidated	**53.7**	**53.8**	**107.5**	**81.3**	**63.7**	**145.0**	**+51.5%**	**+34.9%**

[1] FY2025 results recalculated to reflect slight reallocation between others in Material and certain businesses in FY2026

4. Appendix

Business categories

AsahiKASEI

Business categories from FY 2025

Segment	Business categories	Businesses		
Healthcare	Pharmaceuticals & Life Science	Pharmaceuticals (Japan and U.S.)	Life Science (Bioprocess, CDMO, etc.)	
	Critical Care	ACT (professional defibrillators/AEDs, etc.)	CMS (LifeVest wearable defibrillator, etc.)	
		Sleep apnea diagnosis and treatment devices		
Homes	Housing	Order-built homes	Development[1]	Rental/brokerage[1]
		Remodeling	Overseas homes (North American, Australian)	
	Construction Materials	Insulation	AAC	
Material[2]	Electronics	Electronic materials	Electronic devices	
	Car Interior	Car interior materials		
	Energy & Infrastructure	Separators	Ion-exchange membrane	Hollow-fiber membrane (Microza)
	Comfort Life	High-performance materials (functional additives, etc.)	Fibers	Consumables (Saran Wrap, etc.)
	Performance Chemical	Engineering plastics	Performance coating materials	
	Essential Chemical	Basic materials (petrochemical-related business)	Elastomers	
Others				
Corporate expenses and eliminations[2]				

Overseas sales

AsahiKASEI

- Both of domestic sales and overseas sales increased from previous year with impact of foreign exchange due to weaker yen and higher petrochemical market prices
- Portion of sales in the Americas tending to increase with acquisitions in Healthcare and Homes in the U.S.



Depreciation and amortization

AsahiKASEI

(¥ billion)

	Depreciation and amortization[1]				Amortization of goodwill	
	Q1 2025	of which, PPA amortization[2]	Q1 2026	of which, PPA amortization[2]	Q1 2025	Q1 2026
Healthcare segment	**14.8**	**9.0**	**18.0**	**11.5**	**6.3**	**7.4**
Pharmaceuticals & Life Science	8.1	5.9	10.7	8.1	1.9	2.6
Critical Care	6.8	3.1	7.4	3.4	4.4	4.8
Homes segment	**5.0**	**1.2**	**5.3**	**1.3**	**0.5**	**0.6**
Housing	4.4	1.2	4.7	1.3	0.5	0.6
Construction Materials	0.6	-	0.6	-	-	-
Material segment	**15.9**	**0.9**	**16.5**	**1.0**	**1.3**	**1.4**
Electronics	1.6	-	1.9	-	-	-
Car Interior	2.7	0.9	3.0	1.0	1.2	1.4
Energy & Infrastructure	3.9	-	3.4	-	0.0	0.0
Comfort Life	2.7	-	2.9	-	-	0.0
Performance Chemical	1.9	-	2.1	-	0.0	-
Essential Chemical	1.6	-	1.4	-	-	-
Others in Material	1.3	-	1.8	-	-	0.0
Others	0.3	-	0.3	-	-	-
Corporate expenses and eliminations	3.3	-	3.0	-	-	-
Consolidated	**39.2**	**11.1**	**43.1**	**13.8**	**8.1**	**9.4**

[1] Amortization of goodwill is excluded and shown separately on the right.
[2] Amortization of intangible assets from PPA at the time of acquisition.

Major investments

AsahiKASEI

(FY 2025–)

Segment	Business category	Project	Capacity	Location	Completion of construction (H1 2025 – H2 2028)
Healthcare	Pharmaceuticals & Life Science	Construction of new spinning plant for Planova virus removal filters	–	Nobeoka-shi, Miyazaki, Japan	To be completed and start operations in FY 2029
		Capacity increase at biologics CDMO Bionova	–	California, the U.S.	To be completed in FY 2027 or later
		Establishment of plasmid DNA manufacturing facility by biologics CDMO Bionova	–	Texas, the U.S.	Process development: Completed in H1 2025 GMP[1] manufacturing: To be completed in FY 2026 or later
Material	Electronics	Capacity increase for Pimel photosensitive insulator	–	Fuji-shi, Shizuoka, Japan	To be completed in FY 2027
	Energy & Infrastructure	Capacity increase for Hipore LIB separator coating	600 million m^2/y	North Carolina, the U.S. Hyuga-shi, Miyazaki, Japan	To be completed in H1 2026
		Construction of integrated plant for base film manufacturing and coating of Hipore LIB separator	700 million m^2/y (as coated film)	Ontario, Canada	To be completed in FY 2027[2]
		Construction of new facilities for electrolysis system components (alkaline water and chlor-alkali)	2 GW/y	Kawasaki-shi, Kanagawa, Japan	To be completed in FY 2028
	Others in Material	Renovation of hydroelectric power plants (Suigasaki power plant)	–	Nishiusuki-gun, Miyazaki, Japan	Completed in H1 2025

[1] Manufacturing pharmaceuticals in accordance with Good Manufacturing Practices
[2] Assuming the start of operation to be delayed by 1.5 to 2 years from the initial plan

Major M&A

(FY 2025–)

Segment	Business category	Company	Operations	Cost	Goodwill	Consolidation on statements of income			
						H1 2025	H2 2025	H1 2026	H2 2026
Healthcare	Pharmaceuticals & Life Science	Aicuris Anti-infective Cures AG	R&D of medicine centered on anti-infective therapies	¥144.3 billion	TBD			May 2026	

Progress of structural transformation

(FY 2025–)

Segment	Business category	Project	Execution period (H1 2025 – H2 2028)
Healthcare	Pharmaceuticals & Life Science	Withdrawal of Sepacell leukocyte reduction filter business	Scheduled to cease production and sales in Mar. 2027
Healthcare	Pharmaceuticals & Life Science	Divestiture of diagnostics business	Transferred in Jul. 2025
Healthcare	Critical Care	Divestiture of EMS billing services business	Transferred in Nov. 2025
Material	Energy & Infrastructure	Divestiture of lead battery separator business	Transferred in Dec. 2025
Material	Comfort Life	Business integration of Asahi Kasei Advance (trading company) and Teijin Frontier	Scheduled to integrate businesses in Oct. 2026
Material	Performance Chemical	Discontinuation of hexamethylene diamine production	Scheduled to cease production in Apr. 2027
Material	Essential Chemical	Withdrawal of acrylonitrile and other operations of PTT Asahi Chemical Co., Ltd.	Deconstruction of plant facilities scheduled within a few years
Material	Essential Chemical	Withdrawal of MMA, CHMA, PMMA resin, and SB latex businesses	MMA: Scheduled to cease production and sales in Sep. 2026
			CHMA: Production and sales ceased in Mar. 2026
			PMMA: Scheduled to cease production in Sep. 2026 and sales in Sep. 2027
			SB latex: Scheduled to cease production in Sep. 2027 and sales in Dec. 2027
Material	Essential Chemical	Decarbonization and production capacity optimization of ethylene manufacturing facilities in western Japan	Scheduled to discontinue ethylene production facility of Asahi Kasei Mitsubishi Chemical Ethylene Corp. targeting fiscal 2030
Material	Essential Chemical	Reconfiguration of certain derivatives operations at the Mizushima Works	Discontinuation of production and reconfiguration of supply framework at the Mizushima Works targeting FY 2030

Main KPIs (as of May 2026)

Asahi KASEI

Operating margin	Improved in FY 2025 with income growth in First Priority businesses of Pharmaceuticals and Electronics; further improvement forecasted in FY 2026 with continued income growth despite impact of Aicuris acquisition and in-licensing expenses in Pharmaceuticals
ROIC	Improved in FY 2025 with increased operating income and lower income tax expenses; expected to decline slightly in FY 2026 despite continued income growth with higher income tax expenses and increased interest-bearing debt associated with Aicuris acquisition
ROE	Improved in FY 2025 with increased net income; expected to decline slightly in FY 2026 despite a forecasted increase in net income, as equity is projected to rise with higher retained earnings

■ Operating income, operating margin

(¥ billion)



■ ROIC[1], ROE



[1] ROIC = (operating income − income taxes) ÷ average annual invested capital

Operating income trend[1] (as of May 2026)

AsahiKASEI

- Income structure is more resilient with steady income growth in Homes and income expansion in Healthcare
- Material impacted by severe operating environment after peak in fiscal 2018 but recovering from nadir in fiscal 2022
- Record-high operating income in fiscal 2025 for 2nd consecutive year; aiming for further income growth in fiscal 2026



[1] Results of past fiscal years are reclassified to the current disclosure segments with simplified calculation for reference

[2] Figures for fiscal 2022 retroactively revised to reflect result of PPA (purchase price allocation) completed in Q1 2023 related to Focus Companies acquired on October 31, 2022

[3] Allocation of shared costs has been changed from fiscal 2025.

Note and schedule

- Figures for operating income by business category include intrasegment transactions which are eliminated from the segment totals, while segment totals include shared segment-wide expenses.

Schedule for announcement of financial results for Q2 fiscal 2026

November 5, 2026 (JST)

Disclaimer

The forecasts and estimates shown in this document are dependent on a variety of assumptions and economic conditions.
Plans and figures depicting the future do not imply a guarantee of actual outcomes.

Creating for Tomorrow